KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013
FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).
The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.
Continue Reading →
On 17 May 2011, Knowledge Ecology International (KEI) organized a Briefing on Patents and Health at WIPO’s 16h session of the Standing Committee on Patents (SCP). Continue Reading →
Senators Barrasso, Bingam and Enzi have proposed a prize fund for “competitive technology financial awards for carbon dioxide capture from media in which the concentration of carbon dioxide is dilute.” This bill is is now being proposed as an amendment to an energy bill that might see some action this year. A few things to highlight.
Chicago. October 5, 2006. Thank you. Thanks in particular to Elspeth Revere and Kathy Im.
This award recognizes the collective efforts of our very devoted and talented staff and board. The money and the recognition will make it possible for Knowledge Ecology International (KEI), our new corporate entity, to do more.
Continue Reading →
Thursday, 06 September 2007
Bayer HealthCare AG: Select Joint Ventures, Partnerships, and Alliances with Big Pharma Continue Reading →
KEI remarks on accepting the MacArthur Award for Creative and Effective Institutions
James Love
Knowledge Ecology International
October 5, 2006
Thank you. Thanks in particular to Elspeth Revere and Kathy Im.
This award recognizes the collective efforts of our very devoted and talented staff and board. The money and the recognition will make it possible for Knowledge Ecology International (KEI), our new corporate entity, to do more.
Continue Reading →
Sep 16, 2010 A New Trade Framework for Global Healthcare R&D[1] Access to Medicines and the Financing of Innovations in Health Care Workshop Hosted by the Program on Science, Technology, and Global Development, The Earth Institute at Columbia University, and… Continue Reading →
2000: Paying for health care R&D – Carrots and Sticks James Love* October 19, 2000 *Thirukumaran Balasubramaniam provided research for this paper. Table of Contents Introduction Failures of the Market Investors cannot appropriate all the benefits of research. R&D is… Continue Reading →
KEI statement regarding Gilead’s Acquisition of Kite Pharma.
“Congress should require the NIH to enforce the Bayh-Dole obligation to make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T) treatments available to the public on reasonable terms.
KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is selling the company for $11.9 billion.
Continue Reading →
2016-Mar25-email-Re-Dir-Sig-Response-March-In-Letter 2016-Dec18-Email-Chain-Re-Reasonable-Pricing-Clauses 2016-Dec24-Email-Seeking-Help-Re-NCI-Criticism-Response 2016-Dec25-Email-Seeking-Help-NCI-Rebuttal 2016Mar30-Email-Sen-Sanders-Letter 2016Apr26-Email-Nader-Response 2016Jun27-Email-re-March-in Process 2017-Jan3-Email-Re-Help-NCI-Rebuttal 2017Jan5-Email-Regarding-Kite-License-Applicants 2017Apr24-Email-Chain-Re-Xtandi-Appeal 2017Nov20-email-helping-Allen 2017-Dec7-Email-Re-Placing-Op-Ed 2019Apr16-email-CAR T-information
